Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
<i>Pseudomonas aeruginosa</i> is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) ph...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/10/9/1126 |
| _version_ | 1797520489893068800 |
|---|---|
| author | George L. Daikos Clóvis Arns da Cunha Gian Maria Rossolini Gregory G. Stone Nathalie Baillon-Plot Margaret Tawadrous Paurus Irani |
| author_facet | George L. Daikos Clóvis Arns da Cunha Gian Maria Rossolini Gregory G. Stone Nathalie Baillon-Plot Margaret Tawadrous Paurus Irani |
| author_sort | George L. Daikos |
| collection | DOAJ |
| description | <i>Pseudomonas aeruginosa</i> is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes. Ceftazidime–avibactam is a combination antimicrobial agent comprising ceftazidime, a third-generation semisynthetic cephalosporin, and avibactam, a novel non-β-lactam β-lactamase inhibitor. This review explores the potential role of ceftazidime–avibactam for the treatment of <i>P. aeruginosa</i> infections. Ceftazidime–avibactam has good in vitro activity against <i>P. aeruginosa</i> relative to comparator β-lactam agents and fluoroquinolones, comparable to amikacin and ceftolozane–tazobactam. In Phase 3 clinical trials, ceftazidime–avibactam has generally demonstrated similar clinical and microbiological outcomes to comparators in patients with complicated intra-abdominal infections, complicated urinary tract infections or hospital-acquired/ventilator-associated pneumonia caused by <i>P. aeruginosa</i>. Although real-world data are limited, favourable outcomes with ceftazidime–avibactam treatment have been reported in some patients with MDR and XDR <i>P. aeruginosa</i> infections. Thus, ceftazidime–avibactam may have a potentially important role in the management of serious and complicated <i>P. aeruginosa</i> infections, including those caused by MDR and XDR strains. |
| first_indexed | 2024-03-10T07:57:28Z |
| format | Article |
| id | doaj.art-ccb761aec8f24207bd63743dbf347ac8 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T07:57:28Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-ccb761aec8f24207bd63743dbf347ac82023-11-22T11:46:39ZengMDPI AGAntibiotics2079-63822021-09-01109112610.3390/antibiotics10091126Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>George L. Daikos0Clóvis Arns da Cunha1Gian Maria Rossolini2Gregory G. Stone3Nathalie Baillon-Plot4Margaret Tawadrous5Paurus Irani6Department of Medicine, National and Kapodistrian University of Athens, 115-27 Athens, GreeceHospital Nossa Senhora das Graças, Curitiba 80810-040, PR, BrazilDepartment of Experimental and Clinical Medicine, University of Florence, I-50134 Florence, ItalyPfizer, Groton, CT 06340, USAPfizer, CEDEX 14, 75688 Paris, FrancePfizer, Groton, CT 06340, USAPfizer, Tadworth, Surrey KT20 7NS, UK<i>Pseudomonas aeruginosa</i> is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) phenotypes. Ceftazidime–avibactam is a combination antimicrobial agent comprising ceftazidime, a third-generation semisynthetic cephalosporin, and avibactam, a novel non-β-lactam β-lactamase inhibitor. This review explores the potential role of ceftazidime–avibactam for the treatment of <i>P. aeruginosa</i> infections. Ceftazidime–avibactam has good in vitro activity against <i>P. aeruginosa</i> relative to comparator β-lactam agents and fluoroquinolones, comparable to amikacin and ceftolozane–tazobactam. In Phase 3 clinical trials, ceftazidime–avibactam has generally demonstrated similar clinical and microbiological outcomes to comparators in patients with complicated intra-abdominal infections, complicated urinary tract infections or hospital-acquired/ventilator-associated pneumonia caused by <i>P. aeruginosa</i>. Although real-world data are limited, favourable outcomes with ceftazidime–avibactam treatment have been reported in some patients with MDR and XDR <i>P. aeruginosa</i> infections. Thus, ceftazidime–avibactam may have a potentially important role in the management of serious and complicated <i>P. aeruginosa</i> infections, including those caused by MDR and XDR strains.https://www.mdpi.com/2079-6382/10/9/1126ceftazidime–avibactam<i>Pseudomonas aeruginosa</i>multidrug resistancecomplicated intra-abdominal infectioncomplicated urinary tract infectionhospital-acquired pneumonia |
| spellingShingle | George L. Daikos Clóvis Arns da Cunha Gian Maria Rossolini Gregory G. Stone Nathalie Baillon-Plot Margaret Tawadrous Paurus Irani Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i> Antibiotics ceftazidime–avibactam <i>Pseudomonas aeruginosa</i> multidrug resistance complicated intra-abdominal infection complicated urinary tract infection hospital-acquired pneumonia |
| title | Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i> |
| title_full | Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i> |
| title_fullStr | Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i> |
| title_full_unstemmed | Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i> |
| title_short | Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i> |
| title_sort | review of ceftazidime avibactam for the treatment of infections caused by i pseudomonas aeruginosa i |
| topic | ceftazidime–avibactam <i>Pseudomonas aeruginosa</i> multidrug resistance complicated intra-abdominal infection complicated urinary tract infection hospital-acquired pneumonia |
| url | https://www.mdpi.com/2079-6382/10/9/1126 |
| work_keys_str_mv | AT georgeldaikos reviewofceftazidimeavibactamforthetreatmentofinfectionscausedbyipseudomonasaeruginosai AT clovisarnsdacunha reviewofceftazidimeavibactamforthetreatmentofinfectionscausedbyipseudomonasaeruginosai AT gianmariarossolini reviewofceftazidimeavibactamforthetreatmentofinfectionscausedbyipseudomonasaeruginosai AT gregorygstone reviewofceftazidimeavibactamforthetreatmentofinfectionscausedbyipseudomonasaeruginosai AT nathaliebaillonplot reviewofceftazidimeavibactamforthetreatmentofinfectionscausedbyipseudomonasaeruginosai AT margarettawadrous reviewofceftazidimeavibactamforthetreatmentofinfectionscausedbyipseudomonasaeruginosai AT paurusirani reviewofceftazidimeavibactamforthetreatmentofinfectionscausedbyipseudomonasaeruginosai |